Algert Global LLC Sells 26,207 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Algert Global LLC lowered its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 17.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 127,340 shares of the medical equipment provider’s stock after selling 26,207 shares during the quarter. Algert Global LLC owned about 0.18% of Lantheus worth $10,224,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in the stock. Mackenzie Financial Corp boosted its position in Lantheus by 259.2% during the second quarter. Mackenzie Financial Corp now owns 15,571 shares of the medical equipment provider’s stock valued at $1,250,000 after purchasing an additional 11,236 shares in the last quarter. Diker Management LLC acquired a new stake in Lantheus in the second quarter worth about $419,000. Alpha DNA Investment Management LLC acquired a new stake in Lantheus in the second quarter worth about $412,000. Point72 Europe London LLP acquired a new stake in Lantheus in the second quarter worth about $6,198,000. Finally, Point72 Hong Kong Ltd acquired a new stake in Lantheus in the second quarter worth about $764,000. Institutional investors own 99.06% of the company’s stock.

Insider Transactions at Lantheus

In other news, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $123.15, for a total value of $41,994.15. Following the sale, the chief accounting officer now directly owns 62,216 shares of the company’s stock, valued at $7,661,900.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Lantheus news, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the transaction, the chief accounting officer now owns 62,216 shares of the company’s stock, valued at $7,661,900.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, President Paul Blanchfield sold 2,000 shares of the business’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the transaction, the president now directly owns 98,980 shares in the company, valued at approximately $9,540,682.20. The disclosure for this sale can be found here. Insiders have sold 40,852 shares of company stock valued at $3,922,001 over the last ninety days. Insiders own 1.50% of the company’s stock.

Lantheus Trading Up 2.8 %

Shares of NASDAQ:LNTH opened at $107.36 on Friday. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The stock has a market cap of $7.44 billion, a price-to-earnings ratio of 16.39 and a beta of 0.50. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. The business has a 50-day moving average price of $104.45 and a 200-day moving average price of $85.86.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). The business had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The firm’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.40 earnings per share. Equities analysts predict that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. JMP Securities lowered their price target on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a report on Thursday, August 1st. Leerink Partners raised their price target on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Thursday, July 11th. Redburn Atlantic assumed coverage on Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target for the company. B. Riley raised their price target on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Finally, Truist Financial reduced their price objective on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Lantheus has an average rating of “Moderate Buy” and an average price target of $126.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.